Intellect Neurosciences Inc.
Records under this name other than patents Intellect Neurosciences Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
Showing 1 to 9 of 9 · Back to Intellect Neurosciences Inc.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,703,137 | Treatment of Tauopathies Formerly held In force · High confidence | In force | High confidence | |
| US 6,274,615 | Method for delaying the onset of alheimer's disease and for treatment or delaying the onset of other amyloidosis-related diseases/disorders Term ended Term ended Mar 25, 2019 · From the USPTO record | Term ended | Term ended Mar 25, 2019 | From the USPTO record |
| US 6,395,768 | Uses for indole-3-propionic acids and salts and esters thereof Term ended Term ended Feb 23, 2019 · From the USPTO record | Term ended | Term ended Feb 23, 2019 | From the USPTO record |
| US 7,807,157 | Monoclonal Antibodies and Use Thereof Lapsed on the fee record Ended Oct 5, 2018 · High confidence | Lapsed on the fee record | Ended Oct 5, 2018 | High confidence |
| US 8,173,127 | Specific Antibodies to Amyloid Beta Peptide, Pharmaceutical Compositions and Methods of Use Thereof Term ended Term ended Apr 15, 2018 · Medium confidence | Term ended | Term ended Apr 15, 2018 | Medium confidence |
| US 8,697,076 | Antibodies Selective for Pathological Tau Dimers and Prefibrillar Pathological Tau Oligomers and Their Uses in Treatment, Diagnosis and Monitoring of Tauopathies Lapsed on the fee record Ended Apr 15, 2018 · High confidence | Lapsed on the fee record | Ended Apr 15, 2018 | High confidence |
| US 8,338,379 | Monoclonal antibody and use thereof Lapsed on the fee record Ended Dec 25, 2016 · From the USPTO record | Lapsed on the fee record | Ended Dec 25, 2016 | From the USPTO record |
| US 7,901,689 | Chimeric peptides as immunogens, antibodies thereto, and methods for immunization using chimeric peptides or antibodies Lapsed on the fee record Ended Mar 8, 2015 · From the USPTO record | Lapsed on the fee record | Ended Mar 8, 2015 | From the USPTO record |
| US 5,958,964 | Use of melatonin to prevent cytotoxic effects of amyloid beta protein Term ended Term ended no later than Sep 28, 2019 · Low confidence | Term ended | Term ended no later than Sep 28, 2019 | Low confidence |